Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Quinine, Probenecid, Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Zidovudine
Eligibility Criteria
Inclusion Criteria Patients must: Have symptomatic HIV infection. Be taking zidovudine (AZT), 100 or 200 mg, 5 or 6 x/day. Allowed: History of Pneumocystis carinii pneumonia (PCP). Advanced AIDS related complex (ARC). HIV antibody positive with an absolute CD4 lymphocyte count of < 200 cells/mm3 before study entry. Exclusion Criteria Co-existing Condition: Patients with any of the following conditions are excluded: Glucose-6-phosphate dehydrogenase deficiency. Allergy to sulfa drugs, probenecid, or quinine. Concurrent Medication: Excluded: - Other drugs that might influence the metabolism or renal excretion of zidovudine (AZT).
Sites / Locations
- Johns Hopkins Hosp